tbuckley/cabot-search huggingface dataset:
Antifungal prophylaxis of patients undergoing allogenetic hematopoietic stem cell transplantation in China: a multicenter prospective observational study
Authors: Lei Gao, Yuqian Sun, Fanyi Meng, Mingzhe Han, He Huang, Depei Wu, Li Yu, Hanyun Ren, Xiaojun Huang, Xi Zhang
Journal: Journal of Hematology & Oncology (2016)

Antifungal prophylaxis is currently regarded as the gold standard in situations with allo-genetic hematopoietic stem cell transplantation (allo-HSCT). However, the epidemiological information regarding prophylaxis of invasive fungal diseases (IFDs) is not clear in China. We report the first large-scale (1053 patients) observational study of the prophylaxis and management of IFDs among patients with allo-HSCT in China. The incidence rates of IFD after primary antifungal prophylaxis (PAP), secondary antifungal prophylaxis (SAP), and non-prophylaxis were 22.7 vs. 38.6 vs. 68.6 %, respectively (P = 0.0000). The median time from transplantation to IFD was 45 days in PAP patients, 18 days in SAP patients, and 12 days in non-prophylaxis patients. Aspergillus spp. represents the most common type of fungal infection. Independent risk factors for IFD in allo-HSCT patients with PAP were age, having human leukocyte antigen (HLA)-haploidentical or matched unrelated donor, decreased albumin levels, and the use of itraconazole as the prophylactic antifungal agent. Among SAP transplant recipients, there was no significant risk factor for IFDs. The incidence rates of overall survival (OS) in the PAP, SAP, and no prophylaxis groups were 85.07, 78.80, and 74.82, respectively (P = 0.01). This observational study indicates that prophylaxis of IFD is helpful to reduce the incidence of IFDs and improve the OS of patients after allo-HSCT.
Isovolemic Erythrocytapheresis; Fixed Versus Patient Tailored Volume Exchange in Patients with Polycythemia or Hemochromatosis.
Authors: P.W. Wijermans, L. van Egmond, P.F. Ypma, M.R. Schipperus, Jean-Louis Kerkhoffs, L.H. Bohmer
Journal: Blood (2006)
How to Use Cross-Sectional Imaging to Assess Prognosis in End-Stage Cirrhosis with the Use of Elaar (The Enhanced Liverpool Abdominal Area Ratio) and Software Assisted Liver Volume
Authors: L.C. Smith, S. Alam, C. Farrell, M. Swaminathan, V. Chidambaram, T. Cross
Journal: Journal of Hepatology (2016)
A patient with mild hemophilia A and a high titer antifactor VIII antibody against exogenous factor VIII only: clinical features, surgical management, and partial characterization of the inhibitor
Authors: Kathelijne Peerlinck, Jozef Arnout, Marc Jacquemin, Jean Guy Gilles, Renaud Lavend'homme, Kathleen Freson, Jean-Marie Saint-Remy, Jozef Vermylen
Journal: Blood (1997)
Anti-Inflammatory Action of Glutamine in Acute Liver Failure Induced by Thioacetamide in Rats
Authors: E.G. Schemitt, J.R. Colares, R.M. Hartmann, F. Licks, M. Do Couto Soares, J. De Oliveira Salvi, C.A. Marroni, N.A.P. Marroni
Journal: Journal of Hepatology (2016)
Comment on Narayan. Type 2 Diabetes: Why We Are Winning the Battle but Losing the War? 2015 Kelly West Award Lecture. Diabetes Care 2016;39:653–663
Authors: Gerald Reaven
Journal: Diabetes Care (2016)

In his Kelly West Award Lecture, Narayan suggested that the pathogenesis of type 2 diabetes may be fundamentally different in high-risk populations who vary dramatically in degree of adiposity (1). For example, he raised the possibility that type 2 diabetes was due to “poor insulin secretion” in thin individuals (Asian Indians), whereas the culprit was “poor insulin action” in overweight/obese individuals (Pima Indians). This suggestion does not seem to acknowledge the published evidence from our group and others of the significant differences in degree of insulin resistance that exist among various …
Aflibercept/Folfiri (AF) VS Placebo/Folfiri (PF) In Metastatic Colorectal Cancer (MCRC): Post-Hoc Analysis of Survival Excluding Adjuvant (ADJ)-Only Patients in the Velour Trial
Authors: F. Joulain, U. Iqbal, F. Diamand, E. Van Cutsem, J. Tabernero, C. Allegra
Journal: Annals of Oncology (2012)
Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation
Authors: Yi-Hsin Chan, Chi-Tai Kuo, Yung-Hsin Yeh, Shang-Hung Chang, Lung-Sheng Wu, Hsin-Fu Lee, Hui-Tzu Tu, Lai-Chu See
Journal: Journal of the American College of Cardiology (2016)

It is unclear whether the non–vitamin K antagonist oral anticoagulant agents rivaroxaban and dabigatran are superior to warfarin for efficacy and safety outcomes in Asians with nonvalvular atrial fibrillation (NVAF). The aim of this study was to compare the risk for thromboembolic events, bleeding, and mortality associated with rivaroxaban and dabigatran versus warfarin in Asians with NVAF. A nationwide retrospective cohort study was conducted of consecutive patients with NVAF taking rivaroxaban (n = 3,916), dabigatran (n = 5,921), or warfarin (n = 5,251) using data collected from the Taiwan National Health Insurance Research Database between February 1, 2013 and December 31, 2013. The propensity score weighting method was used to balance covariates across study groups. Patients were followed until the first occurrence of any study outcome or the study end date (December 31, 2013). A total of 3,425 (87%) and 5,301 (90%) patients were taking low-dose rivaroxaban (10 to 15 mg once daily) and dabigatran (110 mg twice daily), respectively. Compared with warfarin, both rivaroxaban and dabigatran significantly decreased the risk for ischemic stroke or systemic embolism (p = 0.0004 and p = 0.0006, respectively), intracranial hemorrhage (p = 0.0007 and p = 0.0005, respectively), and all-cause mortality (p < 0.0001 and p < 0.0001, respectively) during the short follow-up period. In comparing the 2 non–vitamin K antagonist oral anticoagulant agents with each other, no differences were found regarding risk for ischemic stroke or systemic embolism, intracranial hemorrhage, myocardial infarction, or mortality. Rivaroxaban carried a significantly higher risk for hospitalization for gastrointestinal bleeding than dabigatran (p = 0.0416), but on-treatment analysis showed that the risk for hospitalized gastrointestinal bleeding was similar between the 2 drugs (p = 0.5783). In real-world practice among Asians with NVAF, both rivaroxaban and dabigatran were associated with reduced risk for ischemic stroke or systemic embolism, intracranial hemorrhage, and all-cause mortality without significantly increased risk for acute myocardial infarction or hospitalization for gastrointestinal bleeding compared with warfarin.
Validation of the Prognostic Value of Histologic Scoring Systems in Primary Sclerosing Cholangitis; A Multicenter Cohort Study
Authors: E. De Vries, J. Verheij, M. Farkkila, J. Arola, B. Goeppert, P. Schirmacher, D. Gotthardt, P. Trivedi, G. Hirschfield, H. Ytting, B. Vainer, M. Harms, H. van Buuren, K. Biermann, O. Chazouillers, D. Wendum, K. Williamson, R. Chapman, L.M. Wang, S. Hubscher, C. Ponsioen
Journal: Journal of Hepatology (2016)
Alterations in Tumour-Related Immunity in Patients with Intermediate Stage Hepatocellular Carcinoma Undergoing Trans-Arterial Chemoembolisation - a Single-Centre Translational Study
Authors: A. Rao, M. Blahova, D.H. Adams, G. Middleton, S.M. Curbishley, Y.T. Ma
Journal: Journal of Hepatology (2016)
Quantification of HBsAg (HBsAg-Q) in HBeAg-Negative Patients Receiving Nucleos(T)ide Analogues to Predict the Loss of HBsAg
Authors: T. Broquetas, M. García-Retortillo, J.J. Hernández, M. Puigvehí, R. Fernández, N. Cañete, S. Coll, B. Cabrero, M.D. Giménez, F. Bory, R. Solà, J.A. Carrión
Journal: Journal of Hepatology (2016)
Distribution of Radioactivity in Tissues of Normal and Tumor-Bearing Mice Following Intravenous Administration of Radioiodotetrazolium Salt
Authors: S. P. Masouredis, M. B. Shimkin, J. A. McMillan, S. W. Fox
Journal: JNCI Journal of the National Cancer Institute (1950)

Distribution of Radioactivity in Tissues of Normal and Tumor-Bearing Mice Following Intravenous Administration of Radioiodotetrazolium Salt Get access S. P. Masouredis, S. P. Masouredis Search for other works by this author on: Oxford Academic PubMed Google Scholar M. B. Shimkin, M. B. Shimkin Laboratory of Experimental Oncology, National Cancer Institute, National Institutes of Health, U. S. Public Health Service, and the University of California School of Medicine, San Francisco, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar J. A. McMillan, J. A. McMillan Search for other works by this author on: Oxford Academic PubMed Google Scholar S. W. Fox S. W. Fox Department of Chemistry, Iowa State College, Ames, Iowa. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 11, Issue 1, August 1950, Pages 91–96, https://doi.org/10.1093/jnci/11.1.91 Published: 01 August 1950 Article history Received: 26 April 1950 Published: 01 August 1950
Impact of the change in service name from “palliative” to “supportive” care on patient referral at a comprehensive cancer center.
Authors: S. Dalal, S. L. Palla, R. Chacko, L. Nguyen, N. A. Fadul, Z. Li, E. Bruera
Journal: Journal of Clinical Oncology (2010)

9052 Background: Palliative care (PC) consultation services are available in major cancer (CA) hospitals, yet most referrals occur late. Early PC referral can relieve physical and psychosocial distress in CA patients (pts). The term "palliative care" has been considered a barrier to early pt referral. In 2007, we changed the name of the outpatient (OP) and inpatient (IP) PC consultation services to "Supportive Care." The interdisciplinary PC team composition and function did not change. The study objectives were to determine if name change led to increased and earlier referral of pts. Methods: Records of 4,701 consecutive pts with first PC consultation (PC1), pre (Jan'06-Aug'07) and post (Jan'08-Aug'09) name change were analyzed, including demographics, and dates of first registration to hospital (R), advanced CA (aCA) diagnosis (locally recurrent/metastatic), PC1 and death (D). One sample proportions tests, median tests, chi-square tests, and log rank tests were used to identify group differences. Results: Median age was 59 years, 50% males, 90% had solid tumors. Post-name change, we found: a) A 41% increase in PC1 (1950 vs. 2,751 pts, p < 0.001), mainly accounted by increased PC referral (by 98%) in the IP setting (733 vs. 1,451 pts, p < 0.001). b) In OP (but not IP), there was shortened median time (months) from R to PC1 (9.2 vs. 13.2, HR = 0.85, p < 0.001) and from aCA diagnosis to PC1 (5.2 vs. 6.9, HR = 0.82, p < 0.001). c) In OP (but not IP), the overall survival (months) from date of PC1 significantly increased (median 6.2 vs. 4.7, HR = 1.21, p < 0.001). Conclusions: Name change to supportive care was associated with increased pt referrals, mainly in IP setting. In the OP (but not IP), referrals occurred earlier as compared to before name change. The OP setting allowed CA pts earlier access to palliative/supportive care and should be established in cancer centers Pt group Name change N of pts Median age Gender % Survival after PC1 N p yrs p M/F p mths HR (95% CI) p All Pre 1,950 < 0.001 60 0.14 52/48 0.064 2.9 0.99 (0.93-1.06) 0.886 Post 2,751 59 49/51 2.6 1 OP Pre 1,217 0.098 60 0.21 51/49 0.828 4.7 1.21 (1.10-1.33) < 0.001 Post 1,300 59 51/49 6.2 1 IP Pre 733 < 0.001 59 0.89 54/46 0.005 0.9 1.07 (0.97-1.18) 0.152 Post 1,451 58 47/53 1.1 1 No significant financial relationships to disclose.
3D Bioprinting: 3D Bioprinting of Developmentally Inspired Templates for Whole Bone Organ Engineering (Adv. Healthcare Mater. 18/2016)
Authors: Andrew C. Daly, Gráinne M. Cunniffe, Binulal N. Sathy, Oju Jeon, Eben Alsberg, Daniel J. Kelly
Journal: Advanced Healthcare Materials (2016)

A novel biofabrication strategy is described by Daniel R. Kelly and co-workers. On page 2353, 3D bioprinting is used to engineer the developmental precursor to an adult organ. These bioprinted cartilage templates have the capacity to mature into vascularized bone organs in vivo. It is possible to reinforce these immature cartilage precursors with poly-caprolactone microfibres, providing a level of mechanical functionality compatible with implanting such immature organ rudiments into load bearing locations in vivo.
Attacking Oncogene Addiction in B-CLL: Seliciclib First Engages the Mcl-1/Noxa Axis, after Which Gradual Exhaustion of Bcl-2 Protection Leads to Bax Activation.
Authors: Delfine Y.H. Hallaert, Rene Spijker, Margot Jak, Annelieke Jaspers, Ingrid A.M. Derks, Nuno L. Alves, Jan Paul de Boer, Daphne de Jong, Simon R. Green, Rene A.W. van Lier, Marinus H.J. van Oers, Eric Eldering
Journal: Blood (2006)
Performing the Wrong Procedure
Authors: Tami Minnier, Paul Phrampus, Linda Waddell
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Neurologists win Ig Nobel prize for discovering that scratching the other side relieves itching
Authors: Janice Hopkins Tanne
Journal: BMJ (2016)

Neurologists from the University of Lubeck, Germany, have won the 2016 Ig Nobel prize for Medicine for showing that if you deceive the brain you can relieve an itch on the right side of a limb by scratching the equivalent spot on the left side.1

Andreas Sprenger, one of the prize winning researchers, told The BMJ that participants were tricked with mirrors or videos to think that the real itch was being scratched when actually a spot on the opposite arm was. The relief worked only when the participant was deceived.

He said that his group was interested in how perception modified pain. Sprenger noted that the method might be useful when people scratch at a severe itch and damage their skin.

The German scientists were among 10 winners of Ig Nobel awards, which recognise work …
Performance of Fibroscan® in the Assessment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis Patients: Interim Results of a Prospective Multicentre Validation Study
Authors: P.J. Eddowes, Q.M. Anstee, I.N. Guha, E. Tsochatzis, V. Paradis, P. Bedossa, P.N. Newsome
Journal: Journal of Hepatology (2016)
ChREBP regulates fructose-induced glucose production independently of insulin signaling
Authors: Mi-Sung Kim, Sarah A. Krawczyk, Ludivine Doridot, Alan J. Fowler, Jennifer X. Wang, Sunia A. Trauger, Hye-Lim Noh, Hee Joon Kang, John K. Meissen, Matthew Blatnik, Jason K. Kim, Michelle Lai, Mark A. Herman
Journal: Journal of Clinical Investigation (2016)

Obese, insulin-resistant states are characterized by a paradoxical pathogenic condition in which the liver appears to be selectively insulin resistant. Specifically, insulin fails to suppress glucose production, yet successfully stimulates de novo lipogenesis. The mechanisms underlying this dysregulation remain controversial. Here, we hypothesized that carbohydrate-responsive element-binding protein (ChREBP), a transcriptional activator of glycolytic and lipogenic genes, plays a central role in this paradox. Administration of fructose increased hepatic hexose-phosphate levels, activated ChREBP, and caused glucose intolerance, hyperinsulinemia, hypertriglyceridemia, and hepatic steatosis in mice. Activation of ChREBP was required for the increased expression of glycolytic and lipogenic genes as well as glucose-6-phosphatase (G6pc) that was associated with the effects of fructose administration. We found that fructose-induced G6PC activity is a major determinant of hepatic glucose production and reduces hepatic glucose-6-phosphate levels to complete a homeostatic loop. Moreover, fructose activated ChREBP and induced G6pc in the absence of Foxo1a, indicating that carbohydrate-induced activation of ChREBP and G6PC dominates over the suppressive effects of insulin to enhance glucose production. This ChREBP/G6PC signaling axis is conserved in humans. Together, these findings support a carbohydrate-mediated, ChREBP-driven mechanism that contributes to hepatic insulin resistance.
Innate Immune Cell Expression of Pattern Recognition Receptors From β-Thalassemia Patients During Intensive Combination Chelation Therapy
Authors: Patrick B Walter, Paul Harmatz, Annie Higa, Vivian Ng, Marcela G Weyhmiller, Patricia Evans, John B. Porter, Nancy Sweeters, Jackson Price, Alisha Manji, David Killilea, Ashutosh Lal, Elliott Vichinsky
Journal: Blood (2012)
Nitric Oxide For Inhalation Reduces Left Ventricular Remodeling After Myocardial Infarction In Pigs
Authors: Xiaoshun Liu, Peter Pokreisz, Olivier Gheysens, Stefan Ghysels, Frederik Maes, Ellen Caluwe, Hilde Gillijns, Marijke Pellens, Eric Verbeken, Jan Bogaert, Frans Van de Werf, Kenneth D. Bloch, Stefan Janssens
Journal: Circulation (2008)
Long-Term Risk of Hepatocellular Carcinoma during Follow-Up of Patients with Chronic Hepatitis B with Normal Alanine Aminotransferase
Authors: B. Kutala, E. Estrabaud, K. Appourchaux, N. Boyer, C. Castelnau, N. Giuily, M. Martinot-Peignoux, P. Marcellin, T. Asselah
Journal: Journal of Hepatology (2016)
Factor V Binding to Multimerin 1: Modulation by Factor V Activation and Binding Sites in the Factor V C1 and C2 Domains.
Authors: Samira B. Jeimy, Mary Ann Quinn-Allen, Nola Fuller, Kenneth Segers, Alan R. Stafford, Jeffrey I. Weitz, Rodney M. Camire, Gerry A.F. Nicolaes, William H. Kane, Catherine P.M. Hayward
Journal: Blood (2006)
Modelling the Increasing Burden of HCV in Pakistan: The Crucial Need to Act!
Authors: A.G. Lim, H. Qureshi, C. Davies, S. Hamid, A. Trickey, N. Glass, H. Mahmood, Q. Saeed, H. Woodall, C. Mukandavire, M. May, F. Averhoff, P. Vickerman
Journal: Journal of Hepatology (2016)
Non-Invasive Clinical Scores to Identify Liver Fibrosis in Hepatitis Delta Patients
Authors: G.L. Lutterkort, A. Wranke, C. Yurdaydin, E. Budde, R. Lichtinghagen, J. Stift, S. Hardtke, R. Idilman, O. Keskin, A. Koch, M.P. Manns, H.P. Dienes, H. Wedemeyer, B. Heidrich
Journal: Journal of Hepatology (2016)
Clinical significance of tumor-infiltrating lymphocytes in breast cancer
Authors: Sasha E. Stanton, Mary L. Disis
Journal: Journal for ImmunoTherapy of Cancer (2016)

Tumor infiltrating lymphocytes (TIL) play an essential role in mediating response to chemotherapy and improving clinical outcomes in all subtypes of breast cancer. Triple negative breast cancers (TN) are most likely to have tumors with &gt;50&nbsp;% lymphocytic infiltrate, termed lymphocyte predominant breast cancer, and derive the greatest survival benefit from each 10&nbsp;% increase in TIL. The majority of HER2<sup>+</sup> breast cancers have similar level of immune infiltrate as TN breast cancer yet the presence of TILs has not shown the same survival benefit. For HER2<sup>+</sup> breast cancers, type 1&nbsp;T-cells, either increased TBET<sup>+</sup> tumor infiltration or increased type 1 HER2-specific CD4<sup>+</sup> T-cells in the peripheral blood, are associated with better outcomes. Hormone receptor positive HER2 negative tumors tend to have the least immune infiltrate yet are the only breast cancer subtype to show worse prognosis with increased FOXP3 regulatory T-cell infiltrate. Notably, all breast cancer subtypes have tumors with low, intermediate, or high TIL infiltrate. Tumors with high TILs may also have increased PD-L1 expression which might be the reason that TN breast cancer seems to demonstrate the most robust clinical response to immune checkpoint inhibitor therapy but further investigation is needed. Tumors with intermediate or low levels of pre-treatment immune infiltrate, on the other hand, may benefit from an intervention that may increase TIL, particularly type 1&nbsp;T-cells. Examples of these interventions include specific types of cytotoxic chemotherapy, radiation, or vaccine therapy. Therefore, the systematic evaluation of TIL and specific populations of TIL may be able to both guide prognosis and the appropriate sequencing of therapies in breast cancer.
Derek Charles Barker
Authors: Philip Barker, Sheila Barker
Journal: BMJ (2016)

Derek Charles Barker (“Charles”) was born in Watford, Hertfordshire, where his father was a pharmacist. He attended Watford Grammar School. After qualifying for medical school, he completed two years of national service with the Royal Army Medical Corps, followed by house jobs at St Helier Hospital in Carshalton and Queen’s Hospital in Romford. He was awarded the DRCOG in 1950 and always retained his interest in obstetrics.

In 1950 he became a trainee general practitioner under H M Harris in Forty Lane, Wembley Park, Middlesex. Harris then made him an assistant and later a full partner, and when he retired in 1958, Charles bought the house and practice …
Neovascularisation Potential of Blood Outgrowth Endothelial Cells From Patients With Severe Ischemic Cardiomyopathy
Authors: Dieter Dauwe, Kristoff Verdonck, Hilde Gillijns, Ellen Caluwé, Peter Pokreisz, Nick van Gastel, Geert Carmeliet, Maarten Depypere, Frederik Maes, Walter Droogne, Johan Vanhaecke, Aernout Luttun, Stefan Janssens
Journal: Circulation (2013)
Autoimmune Arthritides, Rheumatoid Arthritis, Psoriatic Arthritis, or Peripheral Spondyloarthritis Following Lyme Disease
Authors: Sheila L. Arvikar, Jameson T. Crowley, Katherine B. Sulka, Allen C. Steere
Journal: Arthritis & Rheumatology (2016)

Objective To describe systemic autoimmune joint diseases that develop following Lyme disease, and to compare their clinical features with those of Lyme arthritis (LA). Methods We reviewed records of all adult patients referred to our LA clinic over a 13‐year period, in whom we had diagnosed a systemic autoimmune joint disease following Lyme disease. For comparison, records of patients enrolled in our LA cohort over the most recent 2‐year period were analyzed. Levels of IgG antibodies to Borrelia burgdorferi and to 3 Lyme disease–associated autoantigens were measured. Results We identified 30 patients who had developed a new‐onset systemic autoimmune joint disorder a median of 4 months after Lyme disease (usually manifested by erythema migrans [EM]). Fifteen had rheumatoid arthritis (RA), 13 had psoriatic arthritis (PsA), and 2 had peripheral spondyloarthritis (SpA). The 30 patients typically had polyarthritis, and those with PsA or SpA often had previous psoriasis, axial involvement, or enthesitis. In the comparison group of 43 patients with LA, the usual clinical picture was monoarticular knee arthritis, without prior EM. Most of the patients with systemic autoimmune joint disorders were positive for B burgdorferi IgG antibodies, as detected by enzyme‐linked immunosorbent assay, but had significantly lower titers and lower frequencies of Lyme disease–associated autoantibodies than patients with LA. Prior to our evaluation, these patients had often received additional antibiotics for presumed LA, without benefit. We prescribed antiinflammatory agents, most commonly disease‐modifying antirheumatic drugs, resulting in improvement. Conclusion Systemic autoimmune joint diseases (i.e., RA, PsA, SpA) may follow Lyme disease. Development of polyarthritis after antibiotic‐treated EM, previous psoriasis, or low‐titer B burgdorferi antibodies may provide insight into the correct diagnosis.